Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

by Huan Deng, Yu Huang, Zhengdong Hong, Xuhui Yuan, Zhi Cao, Yiping Wei, Wenxiong Zhang
Published 2019-05-01

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

by Huan Deng, Huan Deng, Wenfeng Liu, Wenfeng Liu, Ting He, Ting He, Zhengdong Hong, Fengming Yi, Yiping Wei, Wenxiong Zhang
Published 2019-06-01

A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-An...

by Huan Deng, Huan Deng, Huan Deng, Meng Li, Meng Li, Qian Wu, Qian Wu, Li Wang, Li Wang, Zhengdong Hong, Fengming Yi, Yiping Wei, Wenxiong Zhang
Published 2020-03-01